SGIOF — SHIONOGI & CO LTD

OTC · Unknown · Unknown · CIK 1281721 ·
Last close
$17.81
Market Cap
$15.16B
52W High
$21.85
52W Low
$16.00
ADV30
113
Next earnings
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 2,576,870,000,000 711,397,000,000 890,666,000,000
Jun 2025
Mar 2025 1,535,349,000,000 374,795,000,000 172,853,000,000
Sep 2024 1,456,729,000,000 303,405,000,000 145,930,000,000

Balance + Analyst (yfinance extras)

Retained Earnings
$1,115,729,000,000
Inventory
$65,477,000,000
Receivables
ST Investments
$270,024,000,000
EBIT TTM
Pretax Income TTM
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$499,677,003,776
EBITDA
$188,007,006,208
Free Cash Flow
$16,777,374,720
Enterprise Value
$-10,858,130,432
Total Cash
$711,397,015,552
Total Debt
$684,394,020,864
Shares Out
850,975,437
Trailing EPS
$1.49
Book Value
$12.24
ROE
13.5%
ROA
4.9%
Div Yield
2.72%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 499,677,000,000 166,725,000,000 205,159,000,000 2,576,870,000,000 890,666,000,000 213,572,000,000
Mar 2025 438,268,000,000 156,604,000,000 170,435,000,000 1,535,349,000,000 172,853,000,000 195,460,000,000
Mar 2024 435,081,000,000 153,312,000,000 162,030,000,000 1,416,918,000,000 164,357,000,000 154,284,000,000
Mar 2023 426,684,000,000 149,004,000,000 184,965,000,000 1,311,800,000,000 189,922,000,000 177,867,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$1.24

Peers — same industry

TickerNameMarket CapLastDaily %
NVMI NOVA LTD. $15.14B $475.90
DSEEY Daiwa Securities Group Inc. $15.39B $11.10
RKLIF RENTOKIL INITIAL PLC /FI $14.92B $5.93
RTO RENTOKIL INITIAL PLC /FI $14.92B $29.64
SGI SOMNIGROUP INTERNATIONAL INC. $15.47B $73.55

News headlines (Yahoo Finance, 1h cache)

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
2026-06-22 12:05 · Yahoo
Shionogi (TSE:4507) Valuation Check As XOCOVA Wins First US FDA Approval For COVID 19 Post Exposure Prophylaxis
2026-06-10 20:06 · Yahoo
New Polymorph of Indomethacin Discovered
2026-06-09 15:00 · Yahoo
Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure
2026-06-01 12:30 · Yahoo
PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices
2026-06-01 12:00 · Yahoo
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
D-Wave CEO on quantum computing's ChatGPT moment, Nvidia, & more
2026-04-14 15:23 · Yahoo
Shionogi’s Fetroja Contract And Data Shift U.S. Growth And Valuation Outlook
2026-04-13 00:21 · Yahoo
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
2026-04-10 11:10 · Yahoo
Shionogi secures $482m BARDA contract to tackle AMR crisis
2026-04-09 10:06 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.